Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial1 passage
• Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease1 passage
• Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial)1 passage
• Complete revascularization in patients with acute myocardial infarction and multivessel disease: Pooled analysis of Kaplan-Meier-derived individual-patient-data1 passage
• Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial1 passage
• Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial1 passage
• Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery1 passage
• Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups1 passage
• Effect of permanent right internal mammary artery occlusion on right coronary artery supply: A randomized placebo-controlled clinical trial1 passage
• Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials1 passage
• Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF1 passage
• Effects of supersaturated oxygen therapy on infarct size and microvascular obstruction following myocardial infarction: A systematic review and meta-analysis1 passage
• Efficacy and safety of human albumin combined with furosemide in acute decompensated heart failure with hepatic dysfunction1 passage
• Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials1 passage
• Exercise treadmill testing for efficacy evaluation in randomized, controlled trials1 passage
• Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial1 passage
• High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction1 passage
• Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: Insights from the PREMIER study1 passage
• Inferior vena CAVA and lung ultraSound-guided therapy in acute heart failure: A randomized pilot study (CAVAL US-AHF study)1 passage
• Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction1 passage
• Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials1 passage
• Pooled analysis of adverse event collection from 4 acute coronary syndrome trials1 passage
• Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial1 passage
• Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease1 passage
• Primary percutaneous coronary intervention within the first hour: Insights from early-treated patients with ST-elevation myocardial infarction1 passage
• Rationale and design of a cluster-randomized controlled trial to evaluate the effects of a community health worker-based program for cardiovascular risk factor control in India1 passage
• Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial1 passage
• Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study1 passage
• Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale1 passage
• Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy1 passage
• Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk1 passage
• Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins1 passage
• Tailored hydration for the prevention of contrast-induced acute kidney injury after coronary angiogram or PCI: A systematic review and meta-analysis1 passage
• The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI1 passage
• The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study1 passage
• Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial1 passage
• Validation of the Seattle angina questionnaire in women with ischemic heart disease1 passage
• Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis1 passage